METHOD OF ASSESSING THE QUALITY OF RECONVALESCENCE IN INFECTIOUS MONONUCLEOSIS IN CHILDREN Russian patent published in 2019 - IPC A61B5/107 A61B5/145 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to children's infectious diseases, and can be used for monitoring of reconvalescence in infectious mononucleosis (IM) in children. Clinical parameters are determined: frequency of acute respiratory diseases per year, liver size increase. Hematological criteria are determined: relative content of atypical mononuclears, monocytes and lymphocytes. Serological criteria are determined: presence of diagnostic titre of IgM to capsid and IgG to nuclear antigen of Epstein-Barr virus. That is followed by assessing the dynamics of infectious mononucleosis by the following parameters: complaints, manifestations of allergy, size of lymph nodes, liver, spleen sizes, total blood analysis, biochemical blood analysis, general urine analysis. Dynamics of the infectious mononucleosis is evaluated by these parameters 1 month after the doctor's visit, 6 months and thereafter every 6 months to 5 years. Infectious mononucleosis clinical course is evaluated by the following parameters: ARVI frequency per year, microbiological disorders, immunologist conclusion. Infectious mononucleosis is evaluated by parameters 1 year after the doctor's visit, and every next year up to 5 years. Dynamics of infectious mononucleosis is assessed by parameters: PCR, ELISA, IgG early, IgG late to Epstein-Barr virus, cytomegalovirus, herpes simplex virus. Infectious mononucleosis dynamics is assessed by these parameters 6 months after the doctor's visit, 1 year and every next year up to 5 years. During normalization of all laboratory and clinical values within one year, removal from dispensary follow-up is performed.

EFFECT: method provides determining infectious process dynamics, differential diagnosis of chronic form and complications of myocardial infarction.

1 cl, 4 tbl, 2 ex